ArticleCancer cell international2019
Identification of a 6-gene signature predicting prognosis for colorectal cancer.
Article in Cancer cell international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 91 citations in OpenAlex.
- BUB1-based risk model predicts prostate cancer prognosis and reveals therapeutic vulnerabilities.European journal of medical research · 2025Article
- Article
- Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets.Frontiers in oncology · 2024Review
- Identification and Validation of Novel Metastasis-Related Immune Gene Signature in Breast Cancer.Breast cancer (Dove Medical Press) · 2024Article
- A cross-cohort computational framework to trace tumor tissue-of-origin based on RNA sequencing.Scientific reports · 2023Article
- Review
- Functional Proteomic Profiling Analysis in Four Major Types of Gastrointestinal Cancers.Biomolecules · 2023Article
- Prognostic model development for classification of colorectal adenocarcinoma by using machine learning model based on feature selection technique boruta.Scientific reports · 2023Article
- Review
- Regularized survival learning and cross-database analysis enabled identification of colorectal cancer prognosis-related immune genes.Frontiers in genetics · 2023Article
- A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.BMC medical informatics and decision making · 2022Article
- Identification of Prognostic Genes in Gliomas Based on Increased Microenvironment Stiffness.Cancers · 2022Article
- Bioinformatics analysis reveals immune prognostic markers for overall survival of colorectal cancer patients: a novel machine learning survival predictive system.BMC bioinformatics · 2022Article
- The methylation modification of m6A regulators contributes to the prognosis of ovarian cancer.Annals of translational medicine · 2022Article
- Identification and validation of an inflammation-related lncRNAs signature for improving outcomes of patients in colorectal cancer.Frontiers in genetics · 2022Article
- Identification of Hub Genes in Colorectal Adenocarcinoma by Integrated Bioinformatics.Frontiers in cell and developmental biology · 2022Article
- Identification of mRNA Signature for Predicting Prognosis Risk of Rectal Adenocarcinoma.Frontiers in genetics · 2022Article
- Apoptosis-Associated Gene Expression Profiling Is One New Prognosis Risk Predictor of Human Rectal Cancer.Disease markers · 2022Article
- Identification of a 5-Nutrient Stress-Sensitive Gene Signature to Predict Survival for Colorectal Cancer.BioMed research international · 2022Article
- Predicting Colorectal Cancer Using Residual Deep Learning with Nursing Care.Contrast media & molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn accurate and robust gene signature is of the utmost importance in assisting oncologists to make a more accurate evaluation in clinical practice. In our study, we extracted key mRNAs significantly related to colorectal cancer (CRC) prognosis and we constructed an expression-based gene signature to predict CRC patients' survival.
methodsmRNA expression profiles and clinicopathological data of colon adenocarcinoma (COAD) cases and rectum adenocarcinoma (READ) were collected from The Cancer Genome Atlas database to investigate gene expression alteration associated to the prognosis of CRC. Differentially expressed mRNAs (DEMs) were detected between COAD/READ and normal tissue samples. Relying on a univariate and multivariate Cox regression analyses, a mRNA panel signature was established and used for predicting the overall survival (OS) in CRC patients. Receiver operating characteristic curve was used to evaluate the prognosis performance of our model through calculating the AUC values corresponding to the 3-year and 5-year survival. To assess the performance of gene signature in the given cancer subgroups (CRC entire cohort, COAD cohort, and READ cohort), a stratified analysis was carried out according to clinical factors.
resultsA total of 5341 and 5594 DEMs were collected from COAD vs. normal tissue samples, and READ vs. normal samples respectively. A univariate regression analysis for the common DEMs between COAD and READ cohorts resulted in 14 common mRNAs related to OS. The multivariate Cox regression analysis revealed that 6 of these mRNAs (EPHA6, TIMP1, IRX6, ART5, HIST3H2BB, and FOXD1) had significant prognostic value allowing the discrimination between high- and low-risk patients, implying poor and good outcomes, respectively. The stratified analysis identified 6-gene signature as an independent prognostic signature in predicting CRC patients' survival.
conclusionsThe 6-gene signature could act as an independent biomarker for survival prediction of CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.